Quotient Sciences Header

Quotient Sciences Header

X

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Filters

×

FILTER:

filter

News Type

filter

Company

filter

Product Type

filter

Deal Size

filter

Upfront Payment

Active Filter(s):

Filters

Reset Filter

All Developments

Product Type

Companies

[{"company":"IRLAB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"IRLAB\\'s IRL790 Receives New Name `mesdopetam\\'","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"SWEDEN","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"IRLAB"},{"company":"IRLAB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"IRLAB's Phase IIa Study with IRL752 is Published in Movement Disorders","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"SWEDEN","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"IRLAB"},{"company":"IRLAB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"IRLAB's Clinical Drug Candidate IRL752 Published in JPET","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"SWEDEN","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"IRLAB"},{"company":"IRLAB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"IRLAB Completes Recruitment in Phase IIb Study of Mesdopetam (IRL790) in Patients with Parkinson's Levodopa-Induced Dyskinesias","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"SWEDEN","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"IRLAB"},{"company":"Tikomed","sponsor":"IQVIA","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"TIKOMED and IQVIA Announce a Strategic Collaboration for The Development of TIKOMED's Lead Drug Platform Candidate ILB","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"SWEDEN","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"Tikomed"},{"company":"Tikomed","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tikomed's Ilb\u00ae Mobilizes and Modulates Key Growth Factors That Trigger a Cascade of Neuroprotective Mechanisms Able to Target All Neuroinflammation-driven Diseases Including ALS","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"SWEDEN","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"Tikomed"},{"company":"OncoZenge","sponsor":"Baltic Sea Foundation","pharmaFlowCategory":"D","amount":"$8.3 million","upfrontCash":"Undisclosed","newsHeadline":"OncoZenge Secures Approximately SEK 70 Million in Financing Ahead of spin-off and separate listing","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"SWEDEN","productType":"Small molecule","productStatus":"Approved","date":"November 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"OncoZenge"}]

IRLAB

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

IRLAB Completes Recruitment in Phase IIb Study of Mesdopetam (IRL790) in Patients with Parkinson's Levodopa-Induced Dyskinesias

Details:

Mesdopetam (IRL790) is a dopamine D3-receptor antagonist being developed for the treatment of levodopa-induced dyskinesias (LIDs), a severe form of troublesome involuntary movements commonly occurring in Parkinson's disease.

Lead Product(s): Mesdopetam

Therapeutic Area: Neurology Product Name: IRL790

Highest Development Status: Phase II Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable September 12, 2022

ASK
US

Upload
your Pipeline Activity

Tikomed

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

Tikomed's Ilb® Mobilizes and Modulates Key Growth Factors That Trigger a Cascade of Neuroprotective Mechanisms Able to Target All Neuroinflammation-driven Diseases Includi...

Details:

These studies show that ILB® releases, re-distributes and modulates the bioactivity of endogeneous heparin-binding growth factors that target disease compromised nervous tissues to initiate a cascade of transcriptional, metabolic and immunological effects.

Lead Product(s): ILB

Therapeutic Area: Neurology Product Name: ILB

Highest Development Status: Phase II Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable August 31, 2022

ASK
US

Upload
your Pipeline Activity

Tikomed

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

TIKOMED and IQVIA Announce a Strategic Collaboration for The Development of TIKOMED's Lead Drug Platform Candidate ILB

Details:

The collaboration will support TikoMed's lead drug platform candidate ILB®, a broad-spectrum small molecule drug candidate with curative potential and clinical development, regulatory and commercial strategies.

Lead Product(s): ILB

Therapeutic Area: Neurology Product Name: ILB

Highest Development Status: Phase II Product Type: Small molecule

Partner/Sponsor/Collaborator: IQVIA

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Collaboration May 05, 2022

ASK
US

Upload
your Pipeline Activity

OncoZenge

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

OncoZenge Secures Approximately SEK 70 Million in Financing Ahead of spin-off and separate listing

Details:

OncoZenge is developing the BUPI project under the BupiZenge ® brand , for the treatment of pain due to oral mucositis, a serious side effect of cancer treatment. BupiZenge ® has shown promising results in a phase 2 study. The capital will be used to finance the phase 3 study.

Lead Product(s): Bupivacaine

Therapeutic Area: Neurology Product Name: BupiZenge

Highest Development Status: Phase II Product Type: Small molecule

Partner/Sponsor/Collaborator: Baltic Sea Foundation

Deal Size: $8.3 million Upfront Cash: Undisclosed

Deal Type: Financing November 16, 2020

ASK
US

Upload
your Pipeline Activity

IRLAB

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

IRLAB's Clinical Drug Candidate IRL752 Published in JPET

Details:

IRL752 is a drug candidate in clinical Phase II and is in development by IRLAB for the treatment of impaired balance (postural dysfunction) and falls in Parkinson's disease (PD-Falls).

Lead Product(s): IRL752

Therapeutic Area: Neurology Product Name: IRL752

Highest Development Status: Phase II Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable July 09, 2020

ASK
US

Upload
your Pipeline Activity

IRLAB

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

IRLAB's Phase IIa Study with IRL752 is Published in Movement Disorders

Details:

The results from the clinical phase IIa study, now published, indicate that IRL752 has the potential to improve balance and reduce the risk of falls.

Lead Product(s): IRL752

Therapeutic Area: Neurology Product Name: Undisclosed

Highest Development Status: Phase II Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable March 23, 2020

ASK
US

Upload
your Pipeline Activity

IRLAB

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

IRLAB's IRL790 Receives New Name `mesdopetam'

Details:

WHO concluded that IRL790 is wholly unique in its mechanism of action and has, therefore, given IRL790 a new INN.

Lead Product(s): Mesdopetam

Therapeutic Area: Neurology Product Name: Undisclosed

Highest Development Status: Phase II Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable February 04, 2020

ASK
US

Upload
your Pipeline Activity

POST ENQUIRY